In this study, we evaluated the effect of lipid-lowering therapy optimization by PCSK9-i on CD34+ cell number and pulse wave velocity in FH subjects; to the best of our knowledge, this is the first study evaluating the role of PCSK9-i on endothelial homeostasis in this population. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.